Markets
BMY

Shire (SHPG) Gets Favorable CHMP Opinion for Revestive

Shire plcSHPG announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for the label expansion of Revestive (teduglutide) 5 mg powder for injection in pediatric patients (aged 1 to 17 years) suffering from short bowel syndrome (SBS).

We note that the European Commission (EC) generally takes the CHMP's opinion into account while reviewing drug applications but is not bound to abide by the same. A final decision from the EC is expected in Aug 2016.

We remind investors that Revestive is already approved in Europe for the treatment of adult patients with SBS who have become stable following a period of intestinal adaptation post surgery. The drug is approved in the U.S. as Gattex for injection for the treatment of adult patients with SBS who are dependent on parenteral support.

We note that Shire acquired NPS Pharmaceuticals Inc. in Feb 2015, thereby adding Revestive/Gattex and Natpara (hypoparathyroidism) to its portfolio and providing a major boost to its gastrointestinal franchise. A label expansion of Revestive for use in the pediatric population will further boost its sales.

Shire has a solid presence in the gastrointestinal, neuroscience and rare disease markets. The impending acquisition of Baxalta BXLT will diversify its presence in the fields of hematology, immunology and oncology.

Shire currently carries a Zacks Rank #2 (Buy). A couple of favorably placed stocks in the healthcare sector are Pfizer Inc. PFE and Bristol-Myers Squibb Company BMY , both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

BAXALTA INC (BXLT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BMY PFE

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More